Ischemic stroke biomarkers in blood

Biomarkers in Medicine

Volumn 7, Issue 1, 2013, Pages 37-47

  Rothstein, Lena ^a   Jickling, Glen C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarkers; blood; gene expression; ischemic stroke

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CLOPIDOGREL; COLLAGENASE 3; D DIMER; DARAPLADIB; DJ 1 PROTEIN; FATTY ACID BINDING PROTEIN; FIBRINOLYTIC AGENT; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOLYTIC ENZYME; MALONALDEHYDE; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN S100B; RNA; TISSUE PLASMINOGEN ACTIVATOR; TROPONIN; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR; WARFARIN;

BLEEDING DISORDER; BRAIN ATHEROSCLEROSIS; BRAIN INFARCTION; BRAIN ISCHEMIA; CARDIOEMBOLIC STROKE; CLINICAL TRIAL (TOPIC); DECOMPRESSIVE CRANIECTOMY; DECOMPRESSIVE HEMICRANIECTOMY; GENETIC IDENTIFICATION; HUMAN; LACUNAR STROKE; NEUROLOGIC DISEASE; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BRAIN ISCHEMIA; FIBRINOLYTIC AGENTS; HUMANS; PROGNOSIS; RISK FACTORS; STROKE;

EID: 84873421554     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.104     Document Type: Review

References (115)

1. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics: 2009 update. A report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 121(7), e46-e215 (2008).
2. Foerch C, Montaner J, Furie KL, Ning MM, Lo EH. Invited article: searching for oracles? Blood biomarkers in acute stroke. Neurology 73(5), 393-399 (2009).
3. Jensen MB, Chacon MR, Sattin JA, Levine RL, Vemuganti R. Potential biomarkers for the diagnosis of stroke. Expert Rev. Cardiovasc. Ther. 7(4), 389-393 (2009).
4. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 40(5), e380-e389 (2009).
5. Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-d-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin. Chem. 49(10), 1752-1762 (2003).
6. Dambinova SA, Khounteev GA, Skoromets AA. Multiple panel of biomarkers for TIA/stroke evaluation. Stroke 33(5), 1181-1182 (2002).
7. Dalmau J, Tuzun E, Wu HY et al. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol. 61(1), 25-36 (2007).
8. Degiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7(11), 1189-1193 (2001).
9. Ganor Y, Goldberg-Stern H, Lerman-Sagie T, Teichberg VI, Levite M. Autoimmune epilepsy: distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/AMPA receptor GluR3, glutamate/NMDA receptor subunit NR2A or double-stranded DNA. Epilepsy Res. 65(1-2), 11-22 (2005).
10. Husebye ES, Sthoeger ZM, Dayan M et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 64(8), 1210-1213 (2005).
11. Dambinova SA, Bettermann K, Glynn T et al. Diagnostic potential of the NMDA receptor peptide assay for acute ischemic stroke. PLoS One 7(7), e42362 (2012).
12. Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke 35(1), 57-63 (2004).
13. Reynolds MA, Kirchick HJ, Dahlen JR et al. Early biomarkers of stroke. Clin. Chem. 49(10), 1733-1739 (2003).
14. Kim MH, Kang SY, Kim MC, Lee WI. Plasma biomarkers in the diagnosis of acute ischemic stroke. Ann. Clin. Lab. Sci. 40(4), 336-341 (2010).
15. Foerch C, Curdt I, Yan B et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J. Neurol. Neurosurg. Psychiatry 77(2), 181-184 (2006).
16. Foerch C, Niessner M, Back T et al. Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin. Chem. 58(1), 237-245 (2012).
17. Allard L, Lescuyer P, Burgess J et al. ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 4(8), 2242-2251 (2004).
18. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 40(1), 77-85 (2009).
19. Moore DF, Li H, Jeffries N et al. Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation 111(2), 212-221 (2005).
20. Tang Y, Xu H, Du X et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J. Cereb. Blood Flow Metab. 26(8), 1089-1102 (2006).
21. Stamova B, Xu H, Jickling G et al. Gene expression profiling of blood for the prediction of ischemic stroke. Stroke 41(10), 2171-2177 (2010).
22. Barr TL, Conley Y, Ding J et al. Genomic biomarkers and cellular pathways of ischemic stroke by RNA gene expression profiling. Neurology 75(11), 1009-1014 (2010).
23. Jin G, Zhou X, Wang H, Wong S. The challenges in blood proteomic biomarker discovery. In: Computational Biology: Issues and Applications in Oncology. Pham TD (Ed.). Springer, NY, USA 273-301(2010).
24. Sideso E, Papadakis M, Wright C et al. Assessing the quality and reproducibility of a proteomic platform for clinical stroke biomarker discovery. Transl. Stroke Res. 1, 304-314 (2010).
25. Dayon L, Turck N, Garci-Berrocoso T et al. Brain extracellular fluid protein changes in acute stroke patients. J. Proteome Res. 10(3), 1043-1051 (2011).
26. Cuadrado E, Rosell A, Colome N et al. The proteome of human brain after ischemic stroke. J. Neuropathol. Exp. Neurol. 69(11), 1105-1115 (2010).
27. Ageno W, Finazzi S, Steidl L et al. Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes. Arch. Intern. Med. 162(22), 2589-2593 (2002).
28. Tombul T, Atbas C, Anlar O. Hemostatic markers and platelet aggregation factors as predictive markers for type of stroke and neurological disability following cerebral infarction. J. Clin. Neurosci. 12(4), 429-434 (2005).
29. Isenegger J, Meier N, Lammle B et al. D-dimers predict stroke subtype when assessed early. Cerebrovasc. Dis. 29(1), 82-86 (2010).
30. Nakagawa K, Yamaguchi T, Seida M et al. Plasma concentrations of brain natriuretic peptide in patients with acute ischemic stroke. Cerebrovasc. Dis. 19(3), 157-164 (2005).
31. Shimizu H, Murakami Y, Inoue S et al. High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation. Stroke 33(4), 1005-1010 (2002).
32. Jickling GC, Xu H, Stamova B et al. Signatures of cardioembolic and large-vessel ischemic stroke. Ann. Neurol. 68(5), 681-692 (2010).
33. Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J. Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke. J. Neurol. Neurosurg. Psychiatry 82(9), 986-992 (2011).
34. Xu H, Tang Y, Liu DZ et al. Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischemic stroke. J. Cereb. Blood Flow Metab. 28(7), 1320-1328 (2008).
35. Suwanwela NC, Chutinet A, Phanthumchinda K. Inflammatory markers and conventional atherosclerotic risk factors in acute ischemic stroke: comparative study between vascular disease subtypes. J. Med. Assoc. Thai. 89(12), 2021-2027 (2006).
36. Hassan A, Hunt BJ, O'sullivan M et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 127(Pt 1), 212-219 (2004).
37. Hassan A, Hunt BJ, O'Sullivan M et al. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain 126(Pt 2), 424-432 (2003).
38. Jickling GC, Stamova B, Ander BP et al. Profiles of lacunar and nonlacunar stroke. Ann. Neurol. 70(3), 477-485 (2011).
39. Knottnerus IL, Winckers K, Ten Cate H et al. Levels of heparin-releasable TFPI are increased in first-ever lacunar stroke patients. Neurology 78(7), 493-498 (2012).
40. Cuadrado-Godia E, Ois A, Garcia-Ramallo E et al. Biomarkers to predict clinical progression in small vessel disease strokes: prognostic role of albuminuria and oxidized LDL cholesterol. Atherosclerosis 219(1), 368-372 (2011).
41. Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H, Schmidt R. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke 36(7), 1410-1414 (2005).
42. Xu H, Stamova B, Jickling G et al. Distinctive RNA expression profiles in blood associated with white matter hyperintensities in brain. Stroke 41(12), 2744-2749 (2010).
43. Miwa K, Tanaka M, Okazaki S, Furukado S, Sakaguchi M, Kitagawa K. Relations of blood inflammatory marker levels with cerebral microbleeds. Stroke 42(11), 3202-3206 (2011).
44. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 39(12), 3372-3377 (2008).
45. Matsukawa N, Yasuhara T, Hara K et al. Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci. 10(1), 126 (2009).
46. Montaner J. Blood biomarkers to guide stroke thrombolysis. Front Biosci. (Elite Ed.) 1, 200-208 (2009).
47. Castellanos M, Leira R, Serena J et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34(1), 40-46 (2003).
48. Montaner J, Alvarez-Sabin J, Molina C et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32(8), 1759-1766 (2001).
49. Montaner J, Alvarez-Sabin J, Molina CA et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32(12), 2762-2767 (2001).
50. Montaner J, Molina CA, Monasterio J et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107(4), 598-603 (2003).
51. Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J. Cereb. Blood Flow Metab. 18(11), 1163-1172 (1998).
52. Demchuk AM, Morgenstern LB, Krieger DW et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 30(1), 34-39 (1999).
53. Uemura S, Matsushita H, Li W et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ. Res. 88(12), 1291-1298 (2001).
54. Barr TL, Latour LL, Lee KY et al. Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 41(3), e123-e128 (2010).
55. Castellanos M, Leira R, Serena J et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 35(7), 1671-1676 (2004).
56. Castellanos M, Sobrino T, Millán M et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke 38(6), 1855-1859 (2007).
57. Ribo M, Montaner J, Molina CA et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 35(9), 2123-2127 (2004).
58. Foerch C, Wunderlich MT, Dvorak F et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 38(9), 2491-2495 (2007).
59. Foerch C, Singer OC, Neumann-Haefelin T et al. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch. Neurol. 62(7), 1130-1134 (2005).
60. Missler U, Wiesmann M, Friedrich C, Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 28(10), 1956-1960 (1997).
61. Wunderlich MT, Lins H, Skalej M, Wallesch CW, Goertler M. Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin. Neurol. Neurosurg. 108(6), 558-563 (2006).
62. Wunderlich MT, Wallesch CW, Goertler M. Release of neurobiochemical markers of brain damage is related to the neurovascular status on admission and the site of arterial occlusion in acute ischemic stroke. J. Neurol. Sci. 227(1), 49-53 (2004).
63. Castillo J, Davalos A, Naveiro J, Noya M. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 27(6), 1060-1065 (1996).
64. Sotgiu S, Zanda B, Marchetti B et al. Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur. J. Neurol. 13(5), 505-513 (2006).
65. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 31(10), 2325-2329 (2000).
66. Montaner J, Rovira A, Molina CA et al. Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J. Cereb. Blood Flow Metab. 23(12), 1403-1407 (2003).
67. Rosell A, Alvarez-Sabin J, Arenillas JF et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 36(7), 1415-1420 (2005).
68. Shenhar-Tsarfaty S, Ben Assayag E, Bova I et al. Interleukin-6 as an early predictor for one-year survival following an ischaemic stroke/transient ischaemic attack. Int. J. Stroke 5(1), 16-20 (2010).
69. Whiteley W, Rumley A, Sattar N. Blood markers and poor outcome after acute cerebrovascular disease: a prospective cohort study. J. Neurol. Neurosurg. Psychiatry 81, e70 (2010).
70. Castellanos M, Sobrino T, Pedraza S et al. High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology 71(23), 1862-1868 (2008).
71. Serena J, Blanco M, Castellanos M et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 36(9), 1921-1926 (2005).
72. Castillo J, Davalos A, Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet 349(9045), 79-83 (1997).
73. Davalos A, Castillo J, Serena J, Noya M. Duration of glutamate release after acute ischemic stroke. Stroke 28(4), 708-710 (1997).
74. Davalos A, Castillo J, Marrugat J et al. Body iron stores and early neurologic deterioration in acute cerebral infarction. Neurology 54(8), 1568-1574 (2000).
75. Castillo J, Rama R, Davalos A. Nitric oxide-related brain damage in acute ischemic stroke. Stroke 31(4), 852-857 (2000).
76. Serena J, Leira R, Castillo J, Pumar JM, Castellanos M, Davalos A. Neurological deterioration in acute lacunar infarctions: the role of excitatory and inhibitory neurotransmitters. Stroke 32(5), 1154-1161 (2001).
77. Castellanos M, Castillo J, Garcia MM et al. Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 33(4), 982-987 (2002).
78. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc. Dis. 27(1), 42-50 (2009).
79. Gorelick PB. Lipoprotein-associated phospholipase A2 and risk of stroke. Am. J. Cardiol. 101(12A), 34F-40F (2008).
80. Ballantyne CM, Hoogeveen RC, Bang H et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch. Intern. Med. 165(21), 2479-2484 (2005).
81. Oei HH, Van Der Meer IM, Hofman A et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 111(5), 570-575 (2005).
82. Wassertheil-Smoller S, Hendrix SL, Limacher M et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289(20), 2673-2684 (2003).
83. Thompson A, Gao P, Orfei L et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375(9725), 1536-1544 (2010).
84. Vahedi K, Vicaut E, Mateo J et al. Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial). Stroke 38(9), 2506-2517 (2007).
85. Foerch C, Otto B, Singer OC et al. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 35(9), 2160-2164 (2004).
86. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabin J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb. Haemost. 91(6), 1146-1151 (2004).
87. Marti-Fabregas J, Borrell M, Cocho D et al. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA. Neurology 65(3), 366-370 (2005).
88. Maas MB, Furie KL. Molecular biomarkers in stroke diagnosis and prognosis. Biomark. Med. 3(4), 363-383 (2009).
89. Rafferty M, Walters MR, Dawson J. Anti-platelet therapy and aspirin resistance-clinically and chemically relevant? Curr. Med. Chem. 17(36), 4578-4586 (2010).
90. Dobaczewski M, Nocun M, Zavodnik I et al. Targeting the urine and plasma determinants of thromboxane A2 metabolism in detection of aspirin effectiveness. Blood Coagul. Fibrinolysis 19(5), 421-428 (2008).
91. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br. J. Haematol. 130(1), 3-10 (2005).
92. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36(5), 1001-1005 (2005).
93. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur. Heart J. 28(14), 1702-1708 (2007).
94. Pare G, Mehta SR, Yusuf S et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363(18), 1704-1714 (2010).
95. Nunnelee JD. Review of an article: the international warfarin pharmacogenetics consortium (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. NEJM 360(8), 753-764. J. Vasc. Nurs. 27(4), 109 (2009).
96. Worthmann H, Dengler R, Schumacher H et al. Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke. Int. J. Mol. Sci. 13(7), 8670-8678 (2012).
97. Hill MD, Jackowski G, Bayer N, Lawrence M, Jaeschke R. Biochemical markers in acute ischemic stroke. CMAJ 162(8), 1139-1140 (2000).
98. Lamers KJ, Vos P, Verbeek MM, Rosmalen F, Van Geel WJ, Van Engelen BG. Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Res. Bull. 61(3), 261-264 (2003).
99. Dvorak F, Haberer I, Sitzer M, Foerch C. Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc. Dis. 27(1), 37-41 (2009).
100. Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR. Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 37(10), 2508-2513 (2006).
101. Di Napoli M, Schwaninger M, Cappelli R et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 36(6), 1316-1329 (2005).
102. Fon EA, Mackey A, Cote R et al. Hemostatic markers in acute transient ischemic attacks. Stroke 25(2), 282-286 (1994).
103. Allard L, Burkhard PR, Lescuyer P et al. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin. Chem. 51(11), 2043-2051 (2005).
104. Uno M, Kitazato KT, Nishi K, Itabe H, Nagahiro S. Raised plasma oxidised LDL in acute cerebral infarction. J. Neurol. Neurosurg. Psychiatry 74(3), 312-316 (2003).
105. Cano CP, Bermudez VP, Atencio HE et al. Increased serum malondialdehyde and decreased nitric oxide within 24 hours of thrombotic stroke onset. Am. J. Ther. 10(6), 473-476 (2003).
106. Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, Allard L, Hochstrasser DF, Sanchez JC. Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol. Cell Proteomics 3(1), 66-72 (2004).
107. Jickling GC, Zhan X, Stamova B et al. Ischemic transient neurological events identified by immune response to cerebral ischemia. Stroke 43(4), 1006-1012 (2012).
108. Zhan X, Jickling GC, Tian Y et al. Transient ischemic attacks characterized by RNA profiles in blood. Neurology 77(19), 1718-1724 (2011).
109. Tuttolomondo A, Di Sciacca R, Di Raimondo D et al. Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site. J. Neuroimmunol. 215(1-2), 84-89 (2009).
110. Mocco J, Choudhri TF, Mack WJ et al. Elevation of soluble intercellular adhesion molecule-1 levels in symptomatic and asymptomatic carotid atherosclerosis. Neurosurgery 48(4), 718-721; discussion 721-712 (2001).
111. Degraba TJ, Siren AL, Penix L et al. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. Stroke 29(7), 1405-1410 (1998).
112. Turaj W, Slowik A, Pulyk R, Adamski M, Szczudlik A. Comparison of plasma concentrations of fibrinogen in patients with ischemic stroke due to large vessel disease and small vessel disease. Neurol. Neurochir. Pol. 40(4), 297-301 (2006).
113. Montaner J, Perea-Gainza M, Delgado P et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 39(8), 2280-2287 (2008).
114. Sato M, Suzuki A, Nagata K, Uchiyama S. Increased von Willebrand factor in acute stroke patients with atrial fibrillation. J. Stroke Cerebrovasc. Dis. 15(1), 1-7 (2006).
115. Jickling GC, Stamova B, Ander BP et al. Prediction of cardioembolic, arterial, and lacunar causes of cryptogenic stroke by gene expression and infarct location. Stroke 43(8), 2036-2041 (2012).